|
1
|
Li W and Urban S: Entry of hepatitis B and
hepatitis D virus into hepatocytes: Basic insights and clinical
implications. J Hepatol. 64(1 Suppl): S32–S40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhang Q, Liao Y, Chen J, Cai B, Su Z, Ying
B, Lu X, Tao C and Wang L: Epidemiology study of HBV genotypes and
antiviral drug resistance in multi-ethnic regions from Western
China. Sci Rep. 5:174132015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartholomeusz A, Tehan BG and Chalmers DK:
Comparisons of the HBV and HIV polymerase and antiviral resistance
mutations. Antivir Ther. 9:149–160. 2004.PubMed/NCBI
|
|
4
|
Dandri M, Lutgehetmann M and Petersen J:
Experimental models and therapeutic approaches for HBV. Semin
Immunopathol. 35:7–21. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zoulim F and Durantel D: Antiviral
therapies and prospects for a cure of chronic hepatitis B. Cold
Spring Harb Perspect Med. 5:a0215012015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zoulim F and Locarnini S: Hepatitis B
virus resistance to nucleos(t)ide analogues. Gastroenterology.
137:1593–1608.e1-2. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cabuang LM, Shaw T, Littlejohn M, Colledge
D, Sozzi V, Soppe S, Warner N, Thompson A, Preiss S, Lam N, et al:
In vitro replication phenotype of a novel (−1G) hepatitis B virus
variant associated with HIV co-infection. J Med Virol.
84:1166–1176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Petersen J, Thompson AJ and Levrero M:
Aiming for cure in HBV and HDV infection. J Hepatol. 65:835–848.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Qin B, Budeus B, Cao L, Wu C, Wang Y,
Zhang X, Rayner S, Hoffmann D, Lu M and Chen X: The amino acid
substitutions rtP177G and rtF249A in the reverse transcriptase
domain of hepatitis B virus polymerase reduce the susceptibility to
tenofovir. Antiviral Res. 97:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aragri M, Alteri C, Battisti A, Di Carlo
D, Minichini C, Sagnelli C, Bellocchi MC, Pisaturo MA, Starace M,
Armenia D, et al: Multiple Hepatitis B virus (HBV) quasispecies and
immune-escape mutations are present in HBV surface antigen and
reverse transcriptase of patients with acute hepatitis B. J Infect
Dis. 213:1897–1905. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caviglia GP, Abate ML, Noviello D, et al:
Hepatitis B core-related antigen kinetics in chronic HBV-genotype-D
infected patients treated with nucleos(t)ide analogues or
pegylated-interferon-alpha. Hepatol Res. 2016.
|
|
12
|
Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ,
Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, et al: Management of
entecavir-resistant chronic hepatitis B with adefovir-based
combination therapies. World J Gastroenterol. 21:10874–10882. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qin B, Zhang B, Zhang X, He T, Xu W, Fu L
and Tu C: Substitution rtq267h of hepatitis B virus increases the
weight of replication and lamivudine resistance. Hepat Mon.
13:e121602013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yahi N, Tamalet C, Tourres C, Tivoli N and
Fantini J: Mutation L210W of HIV-1 reverse transcriptase in
patients receiving combination therapy. Incidence, association with
other mutations and effects on the structure of mutated reverse
transcriptase. J Biomed Sci. 7:507–513. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clavel F and Hance AJ: HIV drug
resistance. N Engl J Med. 350:1023–1035. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Delviks-Frankenberry KA, Lengruber RB,
Santos AF, Silveira JM, Soares MA, Kearney MF, Maldarelli F and
Pathak VK: Connection subdomain mutations in HIV-1 subtype-C
treatment-experienced patients enhance NRTI and NNRTI drug
resistance. Virology. 435:433–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Qin B, He T, Chen Z, Xu W, Pan G and Tu C:
A novel method for the analysis of drug-resistant phenotypes of
hepatitis B virus. Int J Mol Med. 31:975–981. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pokrovsky AG, Pronayeva TR, Fedyuk NV,
Shirokova EA, Khandazhinskaya AL, Tarusova NB, Karpenko IL and
Krayevsky AA: Anti-HIV activity of novel phosphonate derivatives of
AZT, d4T and ddA. Nucleosides, Nucleotides Nucleic Acids.
20:767–769. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Su M, Xiang K, Li Y, Li Y, Deng J, Xu X,
Yan L, Zhuang H and Li T: Higher detection rates of amino acid
substitutions in HBV reverse transcriptase/surface protein
overlapping sequence is correlated with lower serum HBV DNA and
HBsAg levels in HBeAg-positive chronic hepatitis B patients with
subgenotype B2. Infect Genet Evol. 40:275–281. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Khan N, Guarnieri M, Ahn SH, Li J, Zhou Y,
Bang G, Kim KH, Wands JR and Tong S: Modulation of hepatitis B
virus secretion by naturally occurring mutations in the S gene. J
Virol. 78:3262–3270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Abou-Jaoudé G, Molina S, Maurel P and
Sureau C: Myristoylation signal transfer from the large to the
middle or the small HBV envelope protein leads to a loss of HDV
particles infectivity. Virology. 365:204–209. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li MW, Hou W, Wo JE and Liu KZ: Character
of HBV (hepatitis B virus) polymerase gene rtM204V/I and rtL180M
mutation in patients with lamivudine resistance. J Zhejiang Univ
Sci B. 6:664–667. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lucifora J, Xia Y, Reisinger F, Zhang K,
Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz
T, et al: Specific and nonhepatotoxic degradation of nuclear
hepatitis B virus cccDNA. Science. 343:1221–1228. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fourati S, Malet I, Guenzel CA, Soulie C,
Maidou-Peindara P, Morand-Joubert L, Wirden M, Sayon S, Peytavin G,
Simon A, et al: E17A mutation in HIV-1 Vpr confers resistance to
didanosine in association with thymidine analog mutations.
Antiviral Res. 93:167–174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Michel M, Lone YC, Centlivre M, Roux P,
Wain-Hobson S and Sala M: Optimisation of secretion of recombinant
HBsAg virus-like particles: Impact on the development of HIV-1/HBV
bivalent vaccines. Vaccine. 25:1901–1911. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lopez-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pei R, Qin B, Zhang X, Zhu W, Kemper T, Ma
Z, Trippler M, Schlaak J, Chen X and Lu M: Interferon-induced
proteins with tetratricopeptide repeats 1 and 2 are cellular
factors that limit hepatitis B virus replication. J Innate Immun.
6:182–191. 2014. View Article : Google Scholar : PubMed/NCBI
|
